Affinity Asset Advisors, LLC Rocket Pharmaceuticals, Inc. Transaction History

Affinity Asset Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$15.5 - $22.76 $150,024 - $220,294	-9,679 Reduced 3.61%	258,115 $5.05 Million
Q3 2022 Nov 14, 2022	BUY	$12.37 - $18.41 $214,347 - $319,008	17,328 Added 6.92%	267,794 $4.27 Million
Q2 2022 Aug 12, 2022	SELL	$7.96 - $16.64 $394,290 - $824,245	-49,534 Reduced 16.51%	250,466 $3.45 Million
Q1 2022 May 13, 2022	BUY	$13.16 - $23.68 $1.78 Million - $3.2 Million	135,000 Added 81.82%	300,000 $4.76 Million
Q4 2021 Feb 11, 2022	BUY	$21.52 - $36.02 $1.82 Million - $3.05 Million	84,772 Added 105.66%	165,000 $3.6 Million
Q3 2021 Nov 12, 2021	SELL	$27.42 - $48.97 $1.09 Million - $1.95 Million	-39,772 Reduced 33.14%	80,228 $2.4 Million
Q2 2021 Aug 13, 2021	BUY	$39.41 - $47.25 $1.38 Million - $1.65 Million	35,000 Added 41.18%	120,000 $5.32 Million
Q1 2021 May 14, 2021	SELL	$43.34 - $65.91 $866,800 - $1.32 Million	-20,000 Reduced 19.05%	85,000 $3.77 Million
Q4 2020 Feb 12, 2021	BUY	$23.3 - $59.57 $2.45 Million - $6.25 Million	105,000 New	105,000 $5.76 Million

244

108M

262K

159K

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $715M
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.